| Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference |
PRINCETON, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2025 Health Care Conference in Las Vegas, NV on Wednesday, May 14, 2025, at 8:00 a.m. |
globenewswire.com |
2025-05-07 11:00:00 |
Czytaj oryginał (ang.) |
| FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls |
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline. |
zacks.com |
2025-05-02 18:20:36 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript |
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - President & Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Joshua Fleishman - TD Cowen Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham & Company Operator Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics First Quarter 2025 Financial Results Conference Call and Webcast. At this time, participants are in a listen-only mode. |
seekingalpha.com |
2025-05-01 20:24:02 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates |
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.02 per share a year ago. |
zacks.com |
2025-05-01 13:15:43 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates |
1Q 2025 Total Revenue of $125.2M, a 15% Increase Year-over-Year at CER Expanding Portfolio through In-Licensing of DMX-200 Phase 3 Program for Rare Kidney Disease with Significant Market Potential in the U.S. Maintaining 2025 Guidance for Galafold, Reflecting Strong Underlying Demand Updating 2025 Pombiliti + Opfolda Guidance with New Patient Starts Accelerating in 2H Adjusting 2025 Total Revenue Growth Guidance to 15-22% at CER Reiterating GAAP Profitability During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J. |
globenewswire.com |
2025-05-01 11:00:00 |
Czytaj oryginał (ang.) |
| Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States |
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) |
globenewswire.com |
2025-04-30 23:12:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:11 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 |
PRINCETON, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025. |
globenewswire.com |
2025-04-21 11:00:00 |
Czytaj oryginał (ang.) |
| 4 Healthcare Stocks to Buy as the Sector Faces Government Heat |
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies. |
zacks.com |
2025-04-17 13:25:38 |
Czytaj oryginał (ang.) |
| 5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 |
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector. |
zacks.com |
2025-04-07 18:25:39 |
Czytaj oryginał (ang.) |
| AMICUS STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Investors to Contact the Firm |
PHILADELPHIA, April 07, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's long-term investors. |
globenewswire.com |
2025-04-07 12:30:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for April 1st |
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025. |
zacks.com |
2025-04-01 11:55:30 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? |
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2025-03-21 14:36:34 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade) |
Amicus Therapeutics, Inc., with two approved rare disease therapies, shows strong revenue growth and market potential despite a 30% stock decline since 2021. Galafold and Pombiliti+Opfolda are driving revenue, with significant market share and potential label expansions, targeting $1bn revenue by 2028. The company has a solid financial position, minimal near-term competition, and a favorable patent settlement with Teva, ensuring market exclusivity until 2037. |
seekingalpha.com |
2025-03-17 12:21:21 |
Czytaj oryginał (ang.) |
| In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer |
Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. Hampton Dellinger v. Scott Bessent, Secretary of the Treasury, et al. |
globenewswire.com |
2025-03-06 18:31:00 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act |
Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Pamela Bondi, Attorney General of the United States, et al. |
globenewswire.com |
2025-03-03 16:04:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 |
PRINCETON, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in March. |
globenewswire.com |
2025-02-27 09:00:00 |
Czytaj oryginał (ang.) |
| FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth |
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same. |
zacks.com |
2025-02-20 13:40:33 |
Czytaj oryginał (ang.) |
| Compared to Estimates, Amicus Therapeutics (FOLD) Q4 Earnings: A Look at Key Metrics |
Although the revenue and EPS for Amicus Therapeutics (FOLD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-20 12:36:22 |
Czytaj oryginał (ang.) |
| SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term Shareholders to Contact the Firm |
PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law LLC announces that it is investigating Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus”) on behalf of the company's shareholders. Click here for additional information: https://kaskelalaw.com/case/amicus-therapeutics/ Since December 2023, shares of Amicus' common stock have declined in value from a trading price of $14.50 per share to a current trading price of approximately $11.00 per share, a decline of nearly 25% in value. The investigation seeks. |
businesswire.com |
2025-02-19 17:18:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript |
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q4 2024 Earnings Conference Call February 19, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President, Investor Relations Bradley Campbell - President and Chief Executive Officer Sebastien Martel - Chief Business Officer Jeffrey Castelli - Chief Development Officer Simon Harford - Chief Financial Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Dennis Ding - Jefferies Joe Schwartz - Leerink Partners Kristen Kluska - Cantor Fitzgerald Malcolm Kuno - JPMorgan Salveen Richter - Goldman Sachs Gil Blum - Needham & Company Jeff Hung - Morgan Stanley Joshua Fleishman - TD Cowen Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Full Year 2024 Financial Results Conference Call and Webcast. |
seekingalpha.com |
2025-02-19 16:04:47 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates |
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.11 per share a year ago. |
zacks.com |
2025-02-19 11:30:30 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates |
2024 Total Revenue of $528.3M, a 33% Increase Year-over-Year Projecting 2025 Total Revenue Growth of 17-24% at CER Anticipate Achieving Positive GAAP Net Income During H2 2025 Conference Call and Webcast Today at 8:30 a.m. ET PRINCETON, N.J. |
globenewswire.com |
2025-02-19 09:00:00 |
Czytaj oryginał (ang.) |
| Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm |
NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. (NASDAQ: FOLD) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. |
globenewswire.com |
2025-02-17 19:59:00 |
Czytaj oryginał (ang.) |
| Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast? |
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week. |
zacks.com |
2025-02-17 12:30:34 |
Czytaj oryginał (ang.) |
| Insights Into Amicus Therapeutics (FOLD) Q4: Wall Street Projections for Key Metrics |
Besides Wall Street's top -and-bottom-line estimates for Amicus Therapeutics (FOLD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024. |
zacks.com |
2025-02-17 12:20:54 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release |
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-02-12 13:06:21 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025 |
PRINCETON, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 19, 2025, at 8:30 a.m. ET to discuss financial results for the full-year ended December 31, 2024. |
globenewswire.com |
2025-02-10 09:00:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025 |
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at the 21st Annual WORLDSymposium™ 2025, being held February 3-7, 2025 in San Diego, CA. |
globenewswire.com |
2025-02-03 09:00:00 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases |
Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra Cornelius Campbell Burgess v. Administrative Law Judge Jennifer Whang, Federal Deposit Insurance Corp., Acting Chairman Martin J. Gruenberg, Director Michael J. Hsu, Director Rohit Chopra |
globenewswire.com |
2025-01-23 17:38:00 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined |
Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al. Merrick Garland, Attorney General of the United States, et al. v. Texas Top Cop Shop, Inc., et al. |
globenewswire.com |
2025-01-13 15:46:00 |
Czytaj oryginał (ang.) |
| 3 Oversold Biotech Names |
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels. |
seekingalpha.com |
2025-01-13 14:56:03 |
Czytaj oryginał (ang.) |
| Amicus Posts Preliminary 2024 Results, Issues 2025 Outlook |
FOLD reports preliminary fourth-quarter and full-year 2024 total revenues. The company also outlines key strategic goals for 2025. |
zacks.com |
2025-01-13 14:37:09 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook |
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year 1 |
globenewswire.com |
2025-01-12 18:00:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 3:00 p.m. PT. |
globenewswire.com |
2025-01-02 09:00:00 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics: Cheap Heading Into 2025 |
Amicus Therapeutics, Inc.'s shares are down 15% recently despite a profitable 3Q24 and raised FY24 outlook, potentially due to market overreaction. The company markets Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease. Galafold dominates its market segment, and a licensing deal with Teva de-risks future growth, positioning it for a continued revenue increase. |
seekingalpha.com |
2024-12-27 15:33:36 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It |
Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association Food and Drug Administration; et al. v. R.J. Reynolds Vapor Company; RJR Vapor Company L.L.C.; Avail Vapor Texas, L.L.C.; and Mississippi Petroleum Marketers and Convenience Stores Association |
globenewswire.com |
2024-12-23 17:43:00 |
Czytaj oryginał (ang.) |
| HALO or FOLD: Which Is the Better Value Stock Right Now? |
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-12-23 14:46:21 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act |
Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. Texas Top Cop Shop, Inc., et al. v. Merrick Garland, Attorney General of the United States, et al. |
globenewswire.com |
2024-12-18 15:09:00 |
Czytaj oryginał (ang.) |
| Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension |
The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. The Hon. Pauline Newman v. Hon. Kimberly A. Moore, Hon. Sharon Prost, Hon. Richard G. Taranto, et al. |
globenewswire.com |
2024-12-13 17:28:00 |
Czytaj oryginał (ang.) |
| Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday? |
Morgan Stanley downgraded Amicus Therapeutics Inc FOLD. Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. |
benzinga.com |
2024-12-13 16:10:50 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) is a Top-Ranked Momentum Stock: Should You Buy? |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-12-13 12:50:21 |
Czytaj oryginał (ang.) |
| Why Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report? |
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? |
zacks.com |
2024-12-09 08:49:23 |
Czytaj oryginał (ang.) |
| HALO vs. FOLD: Which Stock Is the Better Value Option? |
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two stocks is more attractive to value investors? |
zacks.com |
2024-12-05 14:41:25 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial |
Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. Jeffrey Moats v. National Credit Union Administration Board, Board Member Todd Harper, et al. |
globenewswire.com |
2024-12-03 15:14:00 |
Czytaj oryginał (ang.) |
| HALO vs. FOLD: Which Stock Should Value Investors Buy Now? |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Halozyme Therapeutics (HALO) and Amicus Therapeutics (FOLD). But which of these two companies is the best option for those looking for undervalued stocks? |
zacks.com |
2024-11-19 14:40:21 |
Czytaj oryginał (ang.) |
| NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights |
Saul Ortega & David Rogers v. Office of the Comptroller of the Currency Saul Ortega & David Rogers v. Office of the Comptroller of the Currency |
globenewswire.com |
2024-11-12 21:04:00 |
Czytaj oryginał (ang.) |
| Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated |
FOLD's third-quarter 2024 earnings and sales beat the Zacks Consensus Estimate. The company raises its financial guidance for 2024. |
zacks.com |
2024-11-07 13:40:24 |
Czytaj oryginał (ang.) |
| Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock |
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service. |
zacks.com |
2024-11-07 12:55:35 |
Czytaj oryginał (ang.) |
| Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings |
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-11-06 23:30:30 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript |
Amicus Therapeutics, Inc. (NASDAQ:FOLD ) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET Company Participants Andrew Faughnan - VP, IR Bradley Campbell - President and CEO Sebastien Martel - Chief Business Officer Jeff Castelli - Chief Development Officer Simon Harford - CFO Ellen Rosenberg - Chief Legal Officer Conference Call Participants Ritu Baral - TD Cowen Anupam Rama - JP Morgan Tazeen Ahmad - Bank of America Securities Ellie Merle - UBS Joe Schwartz - Leerink Partners Dae Gon Ha - Stifel Dennis Ding - Jefferies Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Gil Blum - Needham & Company Salveen Richter - Goldman Sachs Operator Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast. |
seekingalpha.com |
2024-11-06 14:54:08 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates |
Amicus Therapeutics (FOLD) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to loss of $0.07 per share a year ago. |
zacks.com |
2024-11-06 11:25:47 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know |
The consensus price target hints at a 51.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-04 12:55:24 |
Czytaj oryginał (ang.) |
| Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 |
PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in November. |
globenewswire.com |
2024-11-01 09:00:00 |
Czytaj oryginał (ang.) |